Watch the interview with Cereno’s CEO Sten R Sörensen below:
Cereno’s CEO: ”CS014 adds potential for cardiovascular disease patients”
Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.
Notes
Episurf improves results and focuses on the US
Dynavox Group acquires RehaMedia for EUR 5,8 million
ProstaLund applies for delisting
XVIVO reports negative growth for Q2
AbbVie pays $700 million for multispecific antibody
NEWSLETTER
NEWS
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
